BIIB
NASDAQBiogen Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks101+54%
2025-12-282026-06-21
Mix5390d
- Other19(36%)
- Insider11(21%)
- SEC Filings9(17%)
- Earnings6(11%)
- Analyst5(9%)
- Leadership3(6%)
Latest news
25 items- PRInternational Regulatory Pathways Have Supported Drug Development Across Biotech and PharmaDENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States. Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes. One example is Eli Lilly (NYSE:LLY), whose oncology therapy Jaypirca adv
- PRNovel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple SclerosisAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate
- PRBiogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire RayThera Inc. for up to $1 billion, consisting of an upfront payment and, predominantly, payments contingent on the achievement of future clinical and regulatory milestones. RayThera's portfolio includes multiple anti-inflammatory assets that could potentially treat immune-mediated conditions across a range of indications. The lead candidate is expected to enter
- INSIDERDirector Hawkins William A was granted 1,505 shares, increasing direct ownership by 17% to 10,365 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- INSIDERDirector Sherwin Stephen A was granted 1,505 shares, increasing direct ownership by 11% to 15,193 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- INSIDERDirector Rowinsky Eric K was granted 1,505 shares, increasing direct ownership by 6% to 25,844 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- INSIDERDirector Mantas Jesus B was granted 1,505 shares, increasing direct ownership by 15% to 11,263 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- INSIDERDirector Langer Susan was granted 1,505 shares, increasing direct ownership by 29% to 6,634 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- INSIDERDirector Patolawala Monish D was granted 1,505 shares, increasing direct ownership by 41% to 5,215 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- INSIDERDirector Pangalos Menelas N converted options into 2,370 shares and was granted 1,505 shares (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- INSIDERDirector Minor Lloyd was granted 1,505 shares, increasing direct ownership by 64% to 3,875 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- INSIDERDirector Freire Maria C was granted 2,005 shares, increasing direct ownership by 29% to 8,820 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- SECBiogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - BIOGEN INC. (0000875045) (Filer)
- SECAmendment: Biogen Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - BIOGEN INC. (0000875045) (Filer)
- ANALYSTBiogen upgraded by Needham with a new price targetNeedham upgraded Biogen from Hold to Buy and set a new price target of $255.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)
- PRBiogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular AtrophyDesignation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenSalanersen is an investigational antisense oligonucleotide dosed once-yearly with the potential to be a meaningful therapy in the future SMA treatment landscape CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced today that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment o
- PREULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus ErythematosusSteroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi
- PRBiogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant CongressesData presentations across multiple kidney diseases illustrate the breadth of Biogen's nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan) and investigational felzartamab, have been accepted for presentation at the 63rd European Renal Association Congress (ERA) and the 2026 American Transplant Congress (ATC). "Our presence across two key medical congresses highlights the momentum of our newly broadened nephrology portfolio, which
- PRUCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus ErythematosusPublication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid taperingResults support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, M
- PRStoke Therapeutics to Present at Upcoming Investor Conferences in JuneStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 9:20 a.m. ET Location: New York, NY Goldman Sachs 47th Annual Global Healthcare Conference 2026 Date: Monday, June 8, 2026 Time: 10:40 a
- PRBiogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's DiseaseThe Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idiopathic Parkinson's diseaseDenali continues to independently conduct the Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Denali Therapeutics Inc. (NASDAQ:DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in indi
- PRBIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law ViolationsBiogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed its primary endpoint.NEW YORK, May 18, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) shareholders lost 6.4% per share on May 14, 2026, when Phase 2 "CELIA" topline data for diranersen missed its primary dose-response endpoint. Investors who held BIIB through the drop are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. On May 14, Biogen released CEL
- ANALYSTEvercore ISI resumed coverage on BiogenEvercore ISI resumed coverage of Biogen with a rating of Outperform
- PRBiogen Completes Acquisition of Apellis PharmaceuticalsCAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen. The acquisition adds two best-in-class commercialized products, EMPAVELI® and SYFOVRE®, significantly bolstering Biogen's near-term growth outlook and accelerating the Company's expansion into nephrology. Together, the products recorded $689 million in net product revenue in 2025. This transaction will strengthen Biogen's revenue and EPS growth potential by being accretive to Bioge
BIIB FAQ
6 questionsWhat does Biogen Inc. do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic...Where does BIIB stock trade?
Biogen Inc. (BIIB) is listed on NASDAQ.What sector and industry is BIIB in?
Biogen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about BIIB?
Biogen Inc. has had 8 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-06-08.What companies are similar to BIIB?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), MRNA (Moderna Inc.). Compare BIIB side-by-side with any of them on Quantisnow.How can I track BIIB on Quantisnow?
Quantisnow aggregates Biogen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BIIB to receive live email and push alerts on every new disclosure.